BPTH

1.16

0.87% 0.01

Dopo l'orario di chiusura: 1.14 -0.02 -1.72%

Bio Path Holdings Inc (BPTH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.15

Aprire:

$1.18

Volume 24 ore:

342.26K

Relative Volume:

0.11

Capitalizzazione di mercato:

$5.00M

Reddito:

Utile/perdita netta:

$-16.08M

Rapporto P/E:

-0.0337

EPS:

-34.43

Flusso di cassa netto:

$-11.54M

1 W Prestazione:

+1.75%

1M Prestazione:

+63.38%

6M Prestazione:

-34.83%

1 anno Prestazione:

-88.19%

Intervallo 1D:

$1.13

$1.21

Intervallo di 1 settimana:

$1.11

$1.34

Portata 52W:

$0.5933

$12.00

Bio Path Holdings Inc Stock (BPTH) Company Profile

Nome

Bio Path Holdings Inc

Settore

Healthcare (1174)

Industria

Biotechnology (669)

Telefono

(832) 742-1357

Indirizzo

4710 BELLAIRE BOULEVARD, BELLAIRE, TX

Dipendente

Cinguettio

Prossima data di guadagno

2024-12-15

Ultimi documenti SEC

BPTH's Discussions on Twitter

Confronta BPTH con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BPTH Bio Path Holdings Inc	1.16	5.00M	0	-16.08M	-11.54M	-34.43
VRTX Vertex Pharmaceuticals Inc	407.11	104.84B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	718.15	78.92B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	621.29	37.15B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	234.28	30.22B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.79	27.76B	3.30B	-501.07M	1.03B	-2.1146

Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-03-11	Iniziato	ROTH Capital	Buy
2017-11-13	Reiterato	H.C. Wainwright	Buy
2016-08-10	Reiterato	Maxim Group	Buy
2016-04-18	Iniziato	Rodman & Renshaw	Buy
2014-06-02	Ripresa	Maxim Group	Buy
2014-05-09	Iniziato	Maxim Group	Buy

Mostra tutto

Bio Path Holdings Inc Borsa (BPTH) Ultime notizie

Jan 03, 2025

Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jan 03, 2025

Dec 29, 2024

Is This Penny Stock a Buy After a 180% Rally? - MSN

Dec 29, 2024

Is This Penny Stock A Buy After A 180% Rally? - Barchart

Dec 29, 2024

Bio-Path Holdings Advances Clinical Trials and Secures $4 Million in Funding - Citybuzz

Dec 29, 2024

Dec 26, 2024

Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World

Dec 26, 2024

Dec 20, 2024

Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes - BioWorld Online

Dec 20, 2024

Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode - Asianet Newsable

Dec 20, 2024

Bio-Path Holdings (BPTH) Surges Over 406% Following Positive Pre - GuruFocus.com

Dec 20, 2024

Dec 19, 2024

Bio-Path More Than Doubles on Preclinical Results of BP1001-A for Obesity - MarketWatch

Dec 19, 2024

Industry Leader Climet Partners with Phizzle; One of the First Joint TCO/ROI Value Proposition in Pharma Manufacturing - Newsfile

Dec 19, 2024

Bio-Path Holdings Shares Were On The Rise: What's Going On? - Benzinga

Dec 19, 2024

Gold Falls Sharply, Lamb Weston Shares Plunge - Benzinga

Dec 19, 2024

Innovative therapies and military tech drive early trading gains - RagingBull

Dec 19, 2024

Stock Market Movers Today • Top Gainers & Losers - Benzinga

Dec 19, 2024

Artificial Intelligence (AI) News Live Feed - StockTitan

Dec 19, 2024

Wall Street-Heavily Traded - WDRB

Dec 19, 2024

Bio-Path (BPTH) Stock Rides High On Promising Trial Results - Stocks Telegraph

Dec 19, 2024

Clinical Trials News Live Feed - StockTitan

Dec 19, 2024

Bio-Path reports potential obesity treatment success - Investing.com

Dec 19, 2024

Bio-Path's Breakthrough Drug Shows Promise in Diabetes Treatment, Phase 1 Trial Set for 2025 - StockTitan

Dec 19, 2024

Dec 18, 2024

Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World

Dec 18, 2024

Dec 17, 2024

VueReal Showcases Industry-First MicroLED Design Reference Kits at CES 2025, Driving Global Innovation Across Key Industries - Newsfile

Dec 17, 2024

Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes - MSN

Dec 17, 2024

Dec 16, 2024

Bullfrog AI CFO Passes Away - Defense World

Dec 16, 2024

Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNEWARK, NJ – December 11, 2024 – Rafael Holdings, Inc. (NYSE: RFL) released its financial results for the first quarter of fiscal year 2025, ended October 31, 2024. The company announ - Defense World

Dec 16, 2024

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients - Defense World

Dec 16, 2024

Dec 14, 2024

Bio-Path Holdings faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Dec 14, 2024

Bio-Path Holdings faces Nasdaq delisting over share price - Investing.com

Dec 14, 2024

Dec 13, 2024

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 - The Kingston Whig-Standard

Dec 13, 2024

Dec 12, 2024

Bio-Path Holdings Shifts Focus to Metabolic Program - TipRanks

Dec 12, 2024

CNB Financial Services, Inc. goes ex dividend tomorrow - MSN

Dec 12, 2024

VueReal Highlights Revolutionary MicroLED Solutions at CES 2025 - Newsfile

Dec 12, 2024

Bio-Path refocuses on diabetes drug amid trial challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 11, 2024

Stonegate Capital Partners Updates Coverage on Aemetis, Inc. (AMTX) Q3 2024 - Newsfile

Dec 11, 2024

Bio-Path refocuses on diabetes drug amid trial challenges - Investing.com India

Dec 11, 2024

Tecnoglass Sets Record Date for Previously-Announced 36% Increase to Fourth Quarter 2024 Dividend - The Manila Times

Dec 11, 2024

Bio-Path Pivots to Diabetes Drug Development, Unveils Strategic Shift in Clinical Pipeline - StockTitan

Dec 11, 2024

Dec 06, 2024

BPTH stock touches 52-week low at $0.6 amid sharp annual decline - Investing.com Canada

Dec 06, 2024

Full Stock Market News from 2024-12-06 - StockTitan

Dec 06, 2024

Nov 29, 2024

Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve

Nov 29, 2024

Nov 26, 2024

StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH) - Defense World

Nov 26, 2024

Nov 23, 2024

Bio-Path Holdings Expands DNAbilize® Technology Applications - MSN

Nov 23, 2024

Nov 21, 2024

Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 21, 2024